E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 5/4/2018 in the Prospect News Structured Products Daily.

New Issue: Credit Suisse sells $815,000 9% contingent coupon autocalls tied to biotech fund

By Susanna Moon

Chicago, May 4 – Credit Suisse AG, London Branch priced $815,000 of contingent coupon autocallable yield notes due July 30, 2019 linked to the SPDR S&P Biotech ETF, according to a 424B2 filing with the Securities and Exchange Commission.

The notes will pay a contingent monthly coupon at an annual rate of 9% if the underlying asset closes at or above its 70% coupon barrier on the observation date for that month.

The notes will be called at par if the underlying fund closes at or above its initial level on any quarterly review date.

The payout at maturity will be par unless the fund ever closes below its 70% knock-in level during the life of the notes, in which case investors will be fully exposed to any losses.

Credit Suisse Securities (USA) LLC is the underwriter.

Issuer:Credit Suisse AG, London Branch
Issue:Contingent coupon autocallable yield notes
Underlying asset:SPDR S&P Biotech ETF
Amount:$815,000
Maturity:July 30, 2019
Coupon:9% annualized, payable monthly if fund closes at or above 70% coupon barrier on observation date for that month
Price:Par
Payout at maturity:Par unless fund ever closes below 70% knock-in level, in which case 1% loss per 1% decline
Call:At par if fund closes at or above its initial level on any quarterly review date
Initial level:$86.35
Trigger level:$60.445, 70% of initial level
Pricing date:April 25
Settlement date:April 30
Agent:Credit Suisse Securities (USA) LLC
Fees:2.5%
Cusip:22550WKL0

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.